Illumina, Inc. · NASDAQ:ILMN

Illumina — Solexa — Merger or Acquisition (November 2006)

22 slides from Illumina's merger presentation, Nov 14, 2006

  1. Slide 1: Creating A Powerful Life Science Franchise

    Creating A Powerful Life Science Franchise 2006 Illumina (c), Inc. Illumina, Sentrix, Array of Arrays, BeadArray, DASL, Infinium, GoldenGate, iSelect, BeadXpress, VeraCode and Making Sense Out of Life are registered trademarks or trademarks of Illumina Inc. November 13, 2006

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Illumina, Inc. ("Illumina") and Solexa, Inc. ("Solexa") caution readers that any forward-looking information is not a guarantee of future performance and actual results could differ

  3. Slide 3: Transaction Overview

    Transaction Overview Offer Price: $14.00 per share Consideration: 100% Stock Collar: +7.5% Pro Forma Ownership: 79% Illumina; 21% Solexa Financing: Illumina has agreed to purchase $50M in newly issued Solexa stock at $9.70 per share Leadership: Jay Flatley, President & CEO John West, SVP & GM Sequen

  4. Slide 4: A Strategically Compelling Opportunity

    A Strategically Compelling Opportunity Whole genome and targeted resequencing are next high- growth markets in life sciences Genotyping and sequencing have natural synergy Digital gene expression will transform the expression market Solexa's "Best-of-Breed" platform primed for broad commercializatio

  5. Slide 5: Combination Expands Target Markets by $1 Billion+

    $1,250 $2,500 Combination Expands Target Markets by $1Billion+ $1 billion sequencing market today Sequencing incremental to genotyping business Market growth Genome centers poised for replacement cycle NCI cancer genome project Targeted resequencing Combined market >$2.25 billion today Total Market

  6. Slide 6: Integration of Sequencing and Genotyping

    Whole Genome Resequencing SNP discovery Rate mutation discovery Whole Genome Genotyping Disease associations 100,000's markers Focused Genotyping Fine mapping Validation 1,000's SNPs SNP Screening Validation 100's SNPs Biomarker discovery Diagnostic Genotyping Low-plex panels PGx Diagnostic Sequenci

  7. Slide 7: Digital Gene Expression will Transform Market

    Digital Gene Expression will Transform Market Solexa sequencing technology allows counting of number of expressed transcripts Counting transcripts yields quantitative comparison between samples and between genes within the same sample Digital data enables creation of databases that are fully compara

  8. Slide 8: Distribution, Chemistry and Content Synergy

    Industry leading genotyping platform Flexible, scalable array technology Targets research market Distribution, Chemistry and Content Synergy

  9. Slide 9: Distribution, Chemistry and Content Synergy

    Industry leading genotyping platform Flexible, scalable array technology Targets research market Launch next few months High sample throughput, low to mid multiplex Targets research and diagnostic market Shared Distribution Shared Chemistry Distribution, Chemistry and Content Synergy

  10. Slide 10: Distribution, Chemistry and Content Synergy

    Distribution, Chemistry and Content Synergy Shared Chemistry Shared Content Shared Distribution Industry leading genotyping platform Flexible, scalable array technology Targets research market Launch next few months High sample throughput, low to mid multiplex Targets research and diagnostic market

  11. Slide 11: Delivers Broad, Novel Application Suite

    Delivers Broad, Novel Application Suite ? Custom Assays ? Linkage V4 ? MHC Panel Human-1 HumanHap300 HumanHap240s HumanHap550 ? 96 Samples x 1400 Genes ? 16 Samples x 1400 Genes GoldenGate(r) (96, 384, 768, 1536 Multiplex) InfiniumTM (Unlimited Multiplexing) Whole Genome (Direct Hybridization) Focus

  12. Slide 12: Solexa's Technology: The 1G Genome Analyzer

    100x lower cost than today's standard Proprietary sequencing by synthesis chemistry Early access customer shipments underway Comprehensive IP portfolio Recent validation - Human X Chromosome Solexa's Technology The 1G Genome Analyzer

  13. Slide 13: Solexa Technical Approach

    Solexa Technical Approach DNA Clusters About 500 DNA copies per cluster Each about 1 micron in diameter Amplify DNA Sequencing Chemistry Extend by one base each step 4 fluorescent colors correspond to the 4 bases Computer-controlled Imaging tens of millions of clusters in parallel Solexa digital ima

  14. Slide 14: Solexa 1G Genome Analyzer

    Solexa 1G Genome Analyzer Solexa 1G Genome Analyzer

  15. Slide 15: Key Technology Advantages

    Key Technology Advantages Solexa Conventional Capillary Systems Basic operating scale Microscopic Macroscopic Sequences in parallel Up to 40 million 96 Instrument time per human genome < 1/2 machine year 50 machine years Consumables per human genome 60 chips Stack of 384-well plates 9x higher than E

  16. Slide 16: Solexa Enhances Illumina's Management Team

    John West Sr. VP & GM Sequencing Over 100 years of total management experience in science, technology, marketing and manufacturing 7 senior managers with direct experience launching leading sequencing platforms 2 independent directors from Solexa joining Illumina Board Solexa Enhances Illumina's Man

  17. Slide 17: Combined Sales and Support Infrastructure Enables Rapid Commercialization

    Combined Sales and Support Infrastructure Enables Rapid Commercialization 33 direct sales capable of selling 1G analyzer 58 Technical support staff capable of working with the 1G analyzer Distributors in Asia / parts of Europe 4 specialists focused on large genome centers

  18. Slide 18: Takes Advantage of Illumina's Financial Strength

    21 Consecutive Quarters of Revenue Growth Market Leading Margins - 30% in Q3 '06 Ending Q3 Cash balance $170M Takes Advantage of Illumina's Financial Strength

  19. Slide 19: Financial Highlights

    Financial Highlights Modestly accretive transaction in 2008 and significantly accretive thereafter Estimated to be 20 to 35% dilutive in 2007, excluding merger related charges Solexa enhances Illumina's trajectory Expanded commercialization of 1G Genome Analyzer in early 2007 VeraCode technology com

  20. Slide 20: Clear Roadmap to Close

    Clear Roadmap to Close Approval of Illumina and Solexa shareholders Customary regulatory approvals and other closing conditions Antitrust review under the Hart-Scott-Rodino Act Expected close by end of Q1 2007

  21. Slide 21: Compelling Strategic Rationale

    Compelling Strategic Rationale Combination creates the only company with leading technologies in genotyping, gene expression and sequencing Greatly expands market opportunity to over $2 billion Utilizes Illumina's world-class infrastructure, financial and technical resources to accelerate the commer

  22. Slide 22: Slide 22

Solexa — Merger or Acquisition (November 2006) on 6ix